Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.45 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | DRD2 | P14416 | 1/20 | 0.45 |
| ▸ | DRD3 | P35462 | 1/20 | 0.45 |
| ▸ | HTR2B | P41595 | 1/20 | 0.45 |
| ▸ | STAT6 | P42226 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 10/20 | 0.43 |
| ▸ | TACR1 | P25103 | 1/20 | 0.43 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17689140 | 0.86 | SMN1; SMN2 (0.62) | SMN1; SMN2TSHRPOLBMAPK1LMNA | |
| SCHEMBL15054692 | 0.83 | SMN1; SMN2 (0.59) | SMN1; SMN2TSHRPOLBMAPK1LMNA | |
| SCHEMBL7418349 | 0.81 | SMN1; SMN2 (0.41) | SMN1; SMN2TSHRLMNAKCNH2ADRA2A | |
| SCHEMBL34475121 | 0.81 | EPAS1 (0.47) | TSHRPOLBMAPK1LMNAHTR2B | |
| Biphenyl SCHEMBL15562954 | 0.80 | POLB (0.51) | TSHRPOLBMAPK1 | |
| SCHEMBL16972466 | 0.80 | ENPP2 (0.40) | SMN1; SMN2LMNAPTGS2PTGS1 | |
| SCHEMBL7414193 | 0.79 | HSD17B10 (0.62) | SMN1; SMN2TSHRLMNAKCNH2ADRA2A | |
| SCHEMBL16822698 | 0.79 | POLB (0.50) | SMN1; SMN2TSHRPOLBMAPK1LMNA | |
| SCHEMBL862980 | 0.77 | POLB (0.73) | SMN1; SMN2TSHRPOLBMAPK1LMNA | |
| SCHEMBL2590043 | 0.77 | SMN1; SMN2 (0.65) | SMN1; SMN2TSHRPOLBMAPK1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2855451-B1 | HETEROCYCLYL PYRIMIDINE ANALOGUES AS TYK2 INHIBITORS | CELLZOME LTD (GB) | 2017-10-04 | — | — | EP | disclosed |
| US-9655897-B2 | Heterocyclyl pyrimidine analogues as TYK2 inhibitors | CELLZOME LIMITED (GB) | 2017-05-23 | — | — | US | disclosed |
| US-9655897-B2 | Heterocyclyl pyrimidine analogues as TYK2 inhibitors | CELLZOME LIMITED (GB) | 2017-05-23 | — | — | US | disclosed |
| US-20160184307-A1 | Heterocyclyl Pyrimidine Analogues As TYK2 Inhibitors | CELLZOME LIMITED (GB) | 2016-06-30 | — | — | US | disclosed |
| US-20160184307-A1 | Heterocyclyl Pyrimidine Analogues As TYK2 Inhibitors | CELLZOME LIMITED (GB) | 2016-06-30 | — | — | US | disclosed |
| US-9296725-B2 | Heterocyclyl pyrimidine analogues as TYK2 inhibitors | CELLZOME LIMITED (GB) | 2016-03-29 | — | — | US | disclosed |
| US-9296725-B2 | Heterocyclyl pyrimidine analogues as TYK2 inhibitors | CELLZOME LIMITED (GB) | 2016-03-29 | — | — | US | disclosed |
| US-20150166513-A1 | Heterocyclyl Pyrimidine Analogues As TYK2 Inhibitors | CELLZOME LIMITED (GB) | 2015-06-18 | — | — | US | disclosed |
| US-20150166513-A1 | Heterocyclyl Pyrimidine Analogues As TYK2 Inhibitors | CELLZOME LIMITED (GB) | 2015-06-18 | — | — | US | disclosed |
| US-8470859-B2 | Iminopyridine derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-06-25 | — | — | US | disclosed |
| EP-2535330-A2 | Iminopyridine derivative and use thereof | Takeda Pharmaceutical Company Limited (JP) | 2012-12-19 | — | — | EP | disclosed |
| US-20100016315-A1 | Iminopyridine Derivative and Use Thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-21 | — | — | US | disclosed |
| EP-2077262-A1 | IMINOPYRIDINE DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2009-07-08 | — | — | EP | disclosed |
| EP-1163214-A1 | GAMMA-KETOACID DIPEPTIDES AS INHIBITORS OF CASPASE-3 | Merck Frosst Canada & Co. (CA) | 2001-12-19 | — | — | EP | disclosed |
| US-6225288-B1 | IMPLICATED IN MODULATING APOPTOSIS; TREATMENT OF:CARDIAC AND CEREBRAL ISCHEMIA/REPERFUSION INJURY, SPINAL CORD INJURY AND ORGAN DAMAGE DURING TRANSPLANTATION, CHRONIC NEURODEGENERATIVE DISEASES, IMMUNODEFICIENCY, DIABETES, ALOPECIA, AGING | MERK FROSST CANADA & CO. (CA) | 2001-05-01 | — | — | US | disclosed |
| WO-2000055127-A1 | GAMMA-KETOACID DIPEPTIDES AS INHIBITORS OF CASPASE-3 | MERCK FROSST CANADA & CO. (CA) | 2000-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016315-A1 | Iminopyridine Derivative and Use Thereof | ADRA1D, ADRB1, ADRB2 | SMN1; SMN2 223/4885TSHR 1427/4885POLB 3613/4885 |
| US-20150166513-A1 | Heterocyclyl Pyrimidine Analogues As TYK2 Inhibitors | TYK2, TXK, IRAK1 | SMN1; SMN2 3356/4885TSHR 601/4885POLB 2597/4885 |
| US-20160184307-A1 | Heterocyclyl Pyrimidine Analogues As TYK2 Inhibitors | TYK2, TXK, IRAK1 | SMN1; SMN2 3356/4885TSHR 601/4885POLB 2597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.